Leerink Chats With Biotech Management, Names 20 Stocks To Buy Now

Leerink recently hosted 24 biopharmaceutical companies at a roundtable event.

Of the 24 companies, Leerink now rates 20 of them as Outperform.

Many of these 20 companies have strong potential catalysts coming relatively soon.

Leerink Partners recently hosted a Rare Disease Roundtable that included fireside chats with 24 biopharmaceutical companies. Following the event, analyst Joseph Schwartz released a report that included a list of 20 Outperform-rated names that attended the roundtable.

Here’s a list of some of the potential catalysts Schwartz sees for these companies.

Highlighted Stocks And Catalysts

Aegerion Pharmaceuticals, Inc. AEGR: The company is guiding conservatively for Juxtapid sales.

Agios Pharmaceuticals Inc AGIO: The company is seeing clinical benefit in solid tumor indications.

Alnylam Pharmaceuticals, Inc. ALNY: The company reports solid enrollment in APOLLO Ph. III trial and positive OLE Phase II data.

Ascendis Pharma A/S ASND: The company is ramping up manufacturing ahead of Ph. III trial in growth deficiency patients.

BioMarin Pharmaceutical Inc. BMRN: The company has a scheduled PDUFA date of December 27.

Cidara Therapeutics Inc CDTX: The company is executing well on CD101 development.

Dicerna Pharmaceuticals Inc DRNA: A decision on the fate of DCR-MYC is expected by the end of 2016.

Other Names

In addition to the specific names mentioned above, Leerink also sees potential upcoming catalysts for the following Outperform-rated names in the space: